Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 4/20 | 0.39 |
| ▸ | PARP1 | P09874 | 5/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.38 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | PDE9A | O76083 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.33 |
| ▸ | CDK4 | P11802 | 3/20 | 0.33 |
| ▸ | CCND1 | P24385 | 3/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18711587 | 0.79 | SPR (0.48) | PDE2APARP1TNKS2TNKSCYP1A2 | |
| SCHEMBL18470932 | 0.76 | PDE2A (0.38) | PDE2APARP1TNKS2TNKSPDE5A | |
| SCHEMBL26155936 | 0.68 | TNKS (0.37) | PARP1TNKS2TNKSPDE5APDE9A | |
| SCHEMBL18168797 | 0.67 | PDE2A (0.32) | PDE2APARP1TNKS2TNKSPDE5A | |
| SCHEMBL12102069 | 0.66 | ADORA3 (0.36) | PARP1TNKS2TNKSCYP1A2ADORA3 | |
| SCHEMBL12102104 | 0.66 | SPR (0.50) | PARP1CYP1A2SPR | |
| SCHEMBL19398960 | 0.65 | PDE9A (0.47) | PDE2APDE5APDE9A | |
| SCHEMBL18689578 | 0.64 | SPR (0.42) | PARP1TNKS2TNKSSPR | |
| SCHEMBL19354193 | 0.64 | PARP1 (0.50) | PARP1TNKS2TNKSCYP1A2ADORA3 | |
| SCHEMBL5863360 | 0.63 | PARP1 (0.38) | PDE2APARP1CDK4CCND1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030118-B2 | Pyrrolotriazinone compounds and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-18 | — | — | US | disclosed |
| US-20030232832-A1 | Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232832-A1 | Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents | CCNB1, NUMA1, CCNA1 | PDE2A 3898/4885PARP1 233/4885TNKS2 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.